208 related articles for article (PubMed ID: 29276754)
1. Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model.
van Koppen A; Verschuren L; van den Hoek AM; Verheij J; Morrison MC; Li K; Nagabukuro H; Costessi A; Caspers MPM; van den Broek TJ; Sagartz J; Kluft C; Beysen C; Emson C; van Gool AJ; Goldschmeding R; Stoop R; Bobeldijk-Pastorova I; Turner SM; Hanauer G; Hanemaaijer R
Cell Mol Gastroenterol Hepatol; 2018; 5(1):83-98.e10. PubMed ID: 29276754
[TBL] [Abstract][Full Text] [Related]
2. A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology.
van den Hoek AM; Verschuren L; Worms N; van Nieuwkoop A; de Ruiter C; Attema J; Menke AL; Caspers MPM; Radhakrishnan S; Salic K; Kleemann R
Cells; 2020 Sep; 9(9):. PubMed ID: 32883049
[TBL] [Abstract][Full Text] [Related]
3. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
[TBL] [Abstract][Full Text] [Related]
4. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
5. Unraveling the Transcriptional Dynamics of NASH Pathogenesis Affecting Atherosclerosis.
van den Hoek AM; Özsezen S; Caspers MPM; van Koppen A; Hanemaaijer R; Verschuren L
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897797
[TBL] [Abstract][Full Text] [Related]
6. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
[TBL] [Abstract][Full Text] [Related]
7. Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr-/-.Leiden Mice.
Morrison MC; Verschuren L; Salic K; Verheij J; Menke A; Wielinga PY; Iruarrizaga-Lejarreta M; Gole L; Yu WM; Turner S; Caspers MPM; Martínez-Arranz I; Pieterman E; Stoop R; van Koppen A; van den Hoek AM; Mato JM; Hanemaaijer R; Alonso C; Kleemann R
Hepatol Commun; 2018 Dec; 2(12):1513-1532. PubMed ID: 30556039
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice.
Gupte AA; Liu JZ; Ren Y; Minze LJ; Wiles JR; Collins AR; Lyon CJ; Pratico D; Finegold MJ; Wong ST; Webb P; Baxter JD; Moore DD; Hsueh WA
Hepatology; 2010 Dec; 52(6):2001-11. PubMed ID: 20938947
[TBL] [Abstract][Full Text] [Related]
9. Key Inflammatory Processes in Human NASH Are Reflected in Ldlr
Morrison MC; Kleemann R; van Koppen A; Hanemaaijer R; Verschuren L
Front Physiol; 2018; 9():132. PubMed ID: 29527177
[No Abstract] [Full Text] [Related]
10. Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis.
Depner CM; Philbrick KA; Jump DB
J Nutr; 2013 Mar; 143(3):315-23. PubMed ID: 23303872
[TBL] [Abstract][Full Text] [Related]
11. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
12. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
13. Neferine ameliorates nonalcoholic steatohepatitis through regulating AMPK pathway.
Wang MY; Zhang SS; An MF; Xia YF; Fan MS; Sun ZR; Zhang LJ; Zhao YL; Sheng J; Wang XJ
Phytomedicine; 2023 Jun; 114():154798. PubMed ID: 37031639
[TBL] [Abstract][Full Text] [Related]
14. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
[TBL] [Abstract][Full Text] [Related]
15. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.
Garcia-Jaramillo M; Spooner MH; Löhr CV; Wong CP; Zhang W; Jump DB
PLoS One; 2019; 14(4):e0214387. PubMed ID: 30943218
[TBL] [Abstract][Full Text] [Related]
16. Time course of western diet (WD) induced nonalcoholic steatohepatitis (NASH) in female and male Ldlr-/- mice.
Spooner MH; Garcia-Jaramillo M; Apperson KD; Löhr CV; Jump DB
PLoS One; 2023; 18(10):e0292432. PubMed ID: 37819925
[TBL] [Abstract][Full Text] [Related]
17. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
[TBL] [Abstract][Full Text] [Related]
18. Is Western Diet-Induced Nonalcoholic Steatohepatitis in Ldlr-/- Mice Reversible?
Lytle KA; Jump DB
PLoS One; 2016; 11(1):e0146942. PubMed ID: 26761430
[TBL] [Abstract][Full Text] [Related]
19. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
Elife; 2023 Jan; 12():. PubMed ID: 36648330
[TBL] [Abstract][Full Text] [Related]
20. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
